SGLT2s for heart failure first, diabetes second

For patients with systemic heart failure but without diabetes, oral SGLT2s are the focus of multiple ongoing phase 3 clinical trials. Also today, influenza activity hits a seasonal high, the U.S. Supreme Court halts a Louisiana abortion law from taking effect, and cilostazol plus aspirin or clopidogrel reduces the risk of recurrent stroke.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify